Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.

Zhifei Biologics is a biological products enterprise integrating vaccine and biological product research and development, production, sales, promotion, distribution, and import/export. It is a listed private vaccine enterprise, with five wholly-owned subsidiaries and one equity-participated subsidiary under its umbrella.
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., as the core R&D and production base of Zhifei Biologics, primarily focuses on human vaccines, which are one of the seven national strategic emerging industries. Currently, the company is dedicated to the R&D and production of novel human vaccines, particularly leading the world in the fields of COVID-19 vaccines and tuberculosis. The company's recombinant subunit COVID-19 vaccine R&D project has been included in the Ministry of Science and Technology's special program on "Public Safety Risk Prevention and Control and Emergency Technical Equipment," with R&D progress at an advanced level globally among similar technologies. The company's leading product, Mycobacterium bovis BCG vaccine for tuberculosis prevention, is one of the few vaccines internationally to have completed human clinical trials for preventing Mycobacterium tuberculosis infection; the recombinant Mycobacterium tuberculosis fusion protein (EC) product has received support from the national "12th Five-Year" and "13th Five-Year" major special projects for infectious disease prevention and control, providing effective means for precise diagnosis and large-scale screening of tuberculosis in China. These two products will fully achieve precise diagnosis and prevention of Mycobacterium tuberculosis infection, providing strong support for building a "Healthy China" and achieving the ultimate goal of "eliminating tuberculosis by 2050" set by the World Health Organization. The company possesses provincial-level enterprise technology centers, provincial vaccine engineering technology research centers, and other R&D institutions, and has established long-term strategic cooperative partnerships with domestic and international renowned institutions such as the National Institute for Food and Drug Control, Chinese Academy of Sciences, University of Science and Technology of China, Shanghai Public Health Clinical Center, Hong Kong University of Science and Technology, and institutions in the United States, Japan, and other countries. Currently, the company undertakes 2 projects under the "National Major New Drug Creation Science and Technology Program" and 4 projects under the "National Major Science and Technology Program for Infectious Disease Prevention and Control." The company possesses strong innovation capabilities and tremendous development potential.

Corporate purpose: Social benefits first, enterprise benefits second
Core values: "Six priorities, six secondaries"
Character first, ability second; Standards first, performance second;
Integrity first, profit second; Discipline first, reasons second;
Quality first, speed second; Collective first, individual second;
Corporate vision: Zhifei Dream, China Dream, Biological Dream, Health Dream